secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001439222-23-000063
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios Q1 2023: PYRUKYND revenue $5.6M, net loss improves to $81M, cash $1.0B
----------------------------------------------------------------------------

- PYRUKYND net revenue of $5.6M in Q1 2023; 127 unique patients enrolled, 89 on therapy.
- Net loss of $81.0M improved from $94.8M in Q1 2022; R&D expense $67.3M, SG&A $28.4M.
- Cash, cash equivalents and marketable securities $1.0B as of March 31, 2023.
- Phase 2 sickle cell data (RISE UP) expected mid-2023; ENERGIZE/ENERGIZE-T enrollment closed.
- Appointed Jeffrey Capello to board; Paul Clancy stepping down effective June 13, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000143922223000063/0001439222-23-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000143922223000063/agio-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001439222-23-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer